- Home
- DBD vs ATAI Comparison
DBD vs ATAI Comparison
Compare DBD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | ATAI |
|---|---|---|
| Founded | 1859 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DBD | ATAI |
|---|---|---|
| Price | $69.94 | $7.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $90.00 | $15.88 |
| AVG Volume (30 Days) | 299.4K | ★ 8.6M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $3,805,700,000.00 | $4,089,000.00 |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $3.25 | N/A |
| P/E Ratio | $116.91 | ★ N/A |
| Revenue Growth | 1.46 | ★ 1227.60 |
| 52 Week Low | $54.48 | $3.27 |
| 52 Week High | $92.09 | $7.45 |
Technical Indicators
Market Signals| Indicator | DBD | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 75.74 |
| Support Level | $67.63 | $3.89 |
| Resistance Level | $72.41 | N/A |
| Average True Range (ATR) | 2.53 | 0.05 |
| MACD | -0.44 | -0.07 |
| Stochastic Oscillator | 24.71 | 87.93 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.